pharmaphorum October 26, 2021
COVID-19 demonstrated the importance of robust supply chains and the dangers of an over reliance on overseas manufacturing. But can the Pharmaceutical Strategy for Europe help to redress the balance?
Only sustainable, robust supply chains and business models will allow innovation to flourish, secure access to medicines, and minimise the industry’s impact on the environment.
The Pharmaceutical Strategy for Europe, which came into effect in November 2020, is a “good first step” towards making this happen, said Richard Daniell, executive vice president and head of Europe Commercial at Teva.
Taking part in a fireside chat at the recent virtual Reuters Events: Pharma 2021 meeting, he explained how the COVID-19 pandemic had been a “wakeup call” for the industry, and spoke...
Today's Sponsors
Today's Sponsor